During the American Association for Cancer Research Annual Meeting held last month in Philadelphia, 30 patient advocates—many of them...
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...
Hear from AACR President Carlos L. Arteaga, MD, and Annual Meeting Program Committee Chairperson Lewis C. Cantley, PhD, about...
In addition to providing a forum for attendees to learn, network, and share information and ideas, the Annual Meeting...
Guest Post by Raymond DuBois, MD, PhD Arizona State University Biodesign Institute
In our first post of this Behind the Scenes series, you read about the years of planning that go...
When the AACR Annual Meeting 2015 begins April 18 in Philadelphia, more than 18,500 attendees will flow seamlessly through...
Guest Post by Matthew J. Sikora, PhD University of Pittsburgh Cancer Institute